Table 1 Clinical and pathological characteristics of 265 patients treated with either ONU or LNU for UTUC

Mean age (SD), years

62.0 (10.7)

62.5 (10.7)

60.2 (10.7)

0.167^a

Gender, n (%)

0.445^b

 Male

198 (74.7)

157 (73.7)

41 (78.8)

 Female

67 (25.3)

56 (26.3)

11 (21.2)

Smoking, n (%)

0.207^b

 No

158 (59.6)

131 (61.5)

27 (51.9)

 Yes

107 (40.4)

82 (38.5)

25 (48.1)

Previous hydronephrosis, n (%)

0.032 ^b

 No

89 (33.6)

65 (30.5)

24 (46.2)

 Yes

176 (66.4)

148 (69.5)

28 (53.8)

Previous bladder urothelial carcinoma, n (%)

<0.001 ^b

 No

225 (84.9)

201 (94.4)

24 (46.2)

 Yes

40 (15.1)

12 (5.6)

28 (53.8)

Concomitant bladder urothelial carcinoma, n (%)

0.274^b

 No

221 (83.4)

175 (82.2)

46 (88.5)

 Yes

44 (16.6)

38 (17.8)

6 (11.5)

Laterality, n (%)

0.598^b

 Left

134 (50.6)

106 (49.8)

28 (53.8)

 Right

131 (49.4)

107 (50.2)

24 (46.2)

Tumor location, n (%)

0.070^b

 Renal pelvis

119 (44.9)

89 (41.8)

30 (57.7)

 Ureter

129 (48.7)

108 (50.7)

21 (40.4)

 Renal pelvis and ureter

17 (6.4)

16 (7.5)

1 (1.9)

Mean tumor size (SD), cm

3.8 (2.0)

3.9 (2.1)

3.3 (1.4)

0.076^a

Tumor focality, n (%)

0.453^b

 Unifocal

156 (58.9)

123 (57.7)

33 (63.5)

 Multifocal

109 (41.1)

90 (42.3)

19 (36.5)

LVI, n(%)

0.964^b

 No

193 (72.8)

155 (72.8)

38 (73.1)

 Yes

72 (27.2)

58 (27.2)

14 (26.9)

Tumor grade, n (%)

0.570^b

 Low

103 (38.9)

81 (38.0)

22 (42.3)

 High

162 (61.1)

132 (62.0)

30 (57.7)

pT stage, n (%)

0.546^b

 pT1

85 (32.1)

65 (30.5)

20 (38.5)

 pT2

56 (21.1)

46 (21.6)

10 (19.2)

 pT3/pT4

124 (46.8)

102 (47.9)

22 (42.3)

pN stage, n (%)

0.613^b

 pN0

109 (41.1)

86 (40.4)

23 (44.2)

 pNx

156 (58.9)

127 (59.6)

29 (55.8)

Distal ureter management, n (%)

<0.001 ^b

 Extravesical

58 (21.9)

55 (25.8)

3 (8.9)

 Open intravesical

154 (58.1)

139 (65.3)

15 (28.8)

 Endoscopic

53 (20.0)

19 (8.9)

34 (65.4)

Adjuvant chemotherapy, n (%)

0.945^b

 No

208 (78.5)

167 (78.4)

41 (78.8)

 Yes

57 (21.5)

46 (21.6)

11 (21.2)